Try our Advanced Search for more refined results
Life Sciences
- 
									October 16, 2025
									Nexus Wants New Trial After Exela Cleared In $89M IP CaseNexus Pharmaceuticals has asked a Delaware federal judge to order a new trial on its patent infringement claims against rival Exela Pharma Sciences, saying a jury that cleared Exela of those claims in September did so "against the great weight of evidence." 
- 
									October 16, 2025
									Bavarian Nordic Gets Sweetened $3.1B Bid But Hurdles LingerDanish vaccine biotech Bavarian Nordic on Thursday urged shareholders to accept a sweetened, roughly $3.1 billion buyout bid from a group of private equity firms, but the shareholder acceptances required for a deal to proceed remain well short of the 75% minimum. 
- 
									October 15, 2025
									Top Del. Judge Details Views On Willful Infringement IssuesA lawsuit cannot provide an accused infringer with the notice needed for a patent owner to allege indirect and willful infringement, and enhanced infringement demands aren't subject to dismissal motions, Delaware's top judge has ruled. 
- 
									October 15, 2025
									Saudi Arabia Fights $100M Arbitral Award To Qatar PharmaThe Kingdom of Saudi Arabia has urged a New York federal judge not to confirm a nearly $100 million arbitral award granted to a Qatari pharmaceutical distributor and its chairman, saying it is immune from suit and did not agree to arbitration. 
- 
									October 15, 2025
									Ga. Justices Revive Suit Over L'Oréal Hair Relaxer Health RisksThe Georgia Supreme Court reversed a decision by the state's Court of Appeals that barred a woman's suit alleging that chemicals in hair relaxers made by L'Oreal USA Inc. and Strength of Nature Global LLC caused her to develop uterine fibroids. 
- 
									October 15, 2025
									Chancery 'Rewrote' $3.4B Merger Deal, J&J Tells Del. JusticesJohnson & Johnson told the Delaware Supreme Court on Wednesday that the Chancery Court "rewrote" its $3.4 billion agreement for the acquisition of surgical robotics firm Auris Health, wrongly using the implied covenant of good faith and fair dealing to impose obligations the company never accepted. 
- 
									October 15, 2025
									Consumer Says Nail Fungus Product Falsely MarketedA North Carolina man hit Arcadia Consumer Healthcare Inc. with a proposed class action in federal court accusing the company of falsely advertising that its product Fungi-Nail is meant to treat nail fungus, although the fine print on the back label says otherwise. 
- 
									October 15, 2025
									Geico Says Cos. Owe $415K For Fraudulent Med Gear SchemeA group of Geico auto insurers told a New York federal court that they are entitled to recoup $415,000 from companies that they allege submitted hundreds of fraudulent no-fault insurance claims, totaling over $1.25 million, for unnecessary durable medical equipment. 
- 
									October 15, 2025
									Greenberg Traurig Lands Wilson Sonsini Life Sciences ProGreenberg Traurig LLP has added a California partner from Wilson Sonsini Goodrich & Rosati with in-house and government legal experience to enhance its capacity to handle matters for clients in life sciences, artificial intelligence, biotechnology and other industries. 
- 
									October 15, 2025
									Some Federal Workers Win Quick Block On Shutdown LayoffsA California federal judge on Wednesday granted a request from two unions representing thousands of federal workers to immediately block the Trump administration from laying them off during the government shutdown, saying she believes the plaintiffs will show that "what's being done here is both illegal and is in excess of authority." 
- 
									October 14, 2025
									NJ, Del. Judges Stress Value Of Local Counsel For IP AttysSix judges with significant experience overseeing pharmaceutical patent litigation in the districts of New Jersey and Delaware urged litigators on Tuesday to rely on the expertise of local counsel if they're hoping to impress the court. 
- 
									October 14, 2025
									Skinny Labels, Orange Book Take Center Stage In IP TalksPatent litigators focused on pharmaceuticals and biotechnology met Tuesday to work through the biggest issues in their industries, including possible reform to skinny label law, frustration with position-switching in litigation, concerns about when to list patents in the U.S. Food and Drug Administration's Orange Book and data on the relatively low impact of new policies at the U.S. Patent and Trademark Office. 
- 
									October 14, 2025
									Full 3rd Circ. Won't Rethink $45M CareDx False Ad CaseThe Third Circuit on Tuesday turned down medical testing company CareDx's request to have a full panel mull whether to reinstate a $45 million jury award in a false advertisement case over genetic testing technology against rival Natera. 
- 
									October 14, 2025
									Relief Concerns Grow As Sectoral Tariff Actions BuildImporters' hopes for relief from industrywide tariffs are lagging alongside the trade deals President Donald Trump is trying to broker for some goods, while the administration's accelerated rollout of sectoral levies is also stoking concerns the government may be hamstringing its onshoring goals. 
- 
									October 14, 2025
									Embryo Loss Class Claims Hinge On Calif. Suit, Judge SaysA Connecticut federal judge may pause a proposed class action blaming CooperSurgical Inc. for embryo losses during in vitro fertilization until a class certification motion is decided in a first-filed case in California, but the plaintiff will have until the end of the month to decide if she wants to proceed with only her direct claims instead. 
- 
									October 14, 2025
									6th Circ. Won't Revive Allergy Tester's Antitrust CaseThe Sixth Circuit refused to revive an allergy testing and treatment company's antitrust case accusing an insurer and a medical group of conspiring to squeeze it out of the market, after finding that doctors are the ones being directly harmed by the alleged activity. 
- 
									October 14, 2025
									Meet HHS General Counsel Michael StuartMichael Stuart, a former chief federal prosecutor for West Virginia, has been confirmed by the U.S. Senate to serve as general counsel for the Department of Health and Human Services, where he has promised to make healthcare fraud enforcement a priority. 
- 
									October 14, 2025
									Attempts To Revive Stroke Treatment Patents Fail At Fed. Circ.The Federal Circuit on Tuesday tossed without analysis a challenge to Patent Trial and Appeal Board rulings that invalidated patents covering a stroke treatment system, letting stand one of the decisions deemed precedential by a former U.S. Patent and Trademark Office director. 
- 
									October 14, 2025
									Freshfields Guides J&J's Planned Orthopedics Unit SpinoffJohnson & Johnson said Tuesday it intends to separate its orthopedics business into a stand-alone company within the next 18 to 24 months, with Freshfields LLP advising on the planned spinoff of the unit. 
- 
									October 14, 2025
									Ōura Valuation Soars To $11B After $900M Financing RoundFitness-tracking ring maker Ōura on Tuesday revealed it had reached a roughly $11 billion valuation after securing over $900 million in a funding round, which it says will help it develop new technologies, speed up artificial intelligence and product innovation, and expand global distribution. 
- 
									October 14, 2025
									Catching Up With Delaware's Chancery CourtLast week at the Delaware Chancery Court, Vice Chancellor Lori W. Will ruled that Carlos Vasallo remains the CEO of Caribevision TV Network LLC, finding that majority investors' attempt to remove him under a defective 2019 agreement was invalid for lack of proper notice. 
- 
									October 14, 2025
									Blood Test Co. Can't Escape Willful Infringement ClaimsA company that makes diagnostic medical tests has been denied a bid to escape from a medical research firm's claims that it willfully infringed patents when a judge held that reading the allegations in combination creates a plausible basis that the company had knowledge of the patents. 
- 
									October 14, 2025
									Covington, Sidley Guide $700M BioCryst Allergic Disease DealBioCryst Pharmaceuticals Inc. will purchase Astria Therapeutics Inc., a biopharmaceutical company focused on therapies for allergic and immunologic diseases, in a cash and stock deal worth about $700 million, the companies announced Tuesday. 
- 
									October 14, 2025
									High Court Won't Hear FDA Stem Cell Regulation FightThe U.S. Supreme Court on Tuesday declined to review a circuit court holding that a stem cell treatment derived from a patient's own tissue is subject to Food, Drug and Cosmetic Act regulations. 
- 
									October 10, 2025
									Some Cases Advance In Latest Stewart Discretionary RulingsDeputy U.S. Patent and Trademark Office Director Coke Morgan Stewart rejected 37 Patent Trial and Appeal Board petitions Friday night, but allowed 17 challenges to proceed. 
Expert Analysis
- 
								
								What Prop 65 Ruling Means For Cosmetics, Personal Care Biz  A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis. 
- 
								Series Adapting To Private Practice: From Va. AUSA To Mid-Law  Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers. 
- 
								
								2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls  Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis. 
- 
								
								Rebutting Price Impact In Securities Class Actions  Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten. 
- 
								
								7 Document Review Concepts New Attorneys Need To Know  For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke. 
- 
								
								Ruling On Labor Peace Law Marks Shift For Cannabis Cos.  Currently on appeal to the Ninth Circuit, an Oregon federal court’s novel decision in Casala v. Kotek, invalidating a state law that requires labor peace agreements as a condition of cannabis business licensure, marks the potential for compliance uncertainty for all cannabis employers in states with labor peace mandates, say attorneys at Sheppard Mullin. 
- 
								
								Fed. Circ. Rulings Refine Patent Claim Construction Standards  Four Federal Circuit patent decisions this year clarify several crucial principles governing patent claim construction, including the importance of prosecution history, and the need for error-free, precise language from claims drafters, say attorneys at Taft. 
- 
								
								How Value-Based Patent Fees May Shape IP Strategies  If the U.S. Patent and Trademark Office implements rumored plans to correlate patent fees with patent value, the financial and strategic consequences would largely depend on the specifics of how, when and how often patent values are assessed, say attorneys at Cleary. 
- 
								
								Agentic AI Puts A New Twist On Attorney Ethics Obligations  As lawyers increasingly use autonomous artificial intelligence agents, disciplinary authorities must decide whether attorney responsibility for an AI-caused legal ethics violation is personal or supervisory, and firms must enact strong policies regarding agentic AI use and supervision, says Grace Wynn at HWG. 
- 
								
								Using Reissue Applications To Strategically Improve Patents  Though reissue applications are an often-overlooked consideration in today's patent environment, they can offer powerful tools for correcting errors, strengthening patent protection, or adapting to evolving business and legal landscapes, says Curtis Powell at Wolf Greenfield. 
- 
								
								FDA Transparency Plans Raise Investor Disclosure Red Flags  The U.S. Food and Drug Administration’s recently announced intent to publish complete response letters for unapproved drugs and devices implicates certain investor disclosure requirements under securities laws, making it necessary for life sciences and biotech companies to adopt robust controls going forward, say attorneys at Arnold & Porter. 
- 
								Series Being A Professional Wrestler Makes Me A Better Lawyer  Pursuing my childhood dream of being a professional wrestler has taught me important legal career lessons about communication, adaptability, oral advocacy and professionalism, says Christopher Freiberg at Midwest Disability. 
- 
								
								Patent Claim Lessons From Fed. Circ.'s Teva Decision  The Federal Circuit's recent decision in Janssen v. Teva is an important precedent for parties drafting patent claims or litigating obviousness where the prior art has potentially overlapping ranges for a claimed element, and may be particularly instructive to patent applicants in the pharmaceutical field, say attorneys at Cooley. 
- 
								Series Law School's Missed Lessons: Adapting To The Age Of AI  Though law school may not have specifically taught us how to use generative artificial intelligence to help with our daily legal tasks, it did provide us the mental building blocks necessary for adapting to this new technology — and the judgment to discern what shouldn’t be automated, says Pamela Dorian at Cozen O'Connor. 
- 
								
								Ch. 11 Ruling Voiding $2M Litigation Funding Sends A Warning.jpg)  A recent Texas bankruptcy court decision that a postconfirmation litigation trust has no obligations to repay a completely drawn down $2 million litigation funding agreement serves as a warning for estate administrators and funders to properly disclose the intended financing, say attorneys at Kleinberg Kaplan.